Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)

Share this content:
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
 
Sponsors and Collaborators
M.D. Anderson Cancer Center
Biosite
 
Contact
MD Anderson CCOP Network Sites
713-563-0276
 
Michael Fisch, MD, MPH
713-563-9905
 
Investigators
Michael Fisch, MD,MPH
UT MD Anderson Cancer Center
 
Daniel J. Lenihan, MD
Vanderbilt University, Division of Cardiovascular Medicine
  
ClinicalTrials.gov Identifier
NCT01311843

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs